Single-use Bioprocessing Companies

The global single-use bioprocessing market is projected to reach USD 33.67 billion by 2030 from USD 18.01 billion in 2025, registering a CAGR of 13.3% between 2025 and 2030. Growth of the single-use bioprocessing market can be attributed to the growing adoption of single-use technologies among contract development & manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs), increased productivity, and reduced risk of cross-contamination. Furthermore, the requirement for low capital investment and environmental sustainability attributes due to reduced water and energy consumption further contributes to market growth.

The global single-use bioprocessing market is consolidated, with Sartorius AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), and Merck KGaA (Germany) accounting for 50.0–55.0% of the market share globally. These market players have adopted growth strategies, such as product launches, acquisitions, agreements, collaborations, and geographical expansions, to strengthen their position in the global single-use bioprocessing market.

To know about the assumptions considered for the study download the pdf brochure

For instance, in March 2024, Merck KGaA invested around USD 15 million to expand its M Lab Collaboration Center in Shanghai. The new facility will add a new biology application lab, a process development training center, and an upstream application lab to the existing M Lab Collaboration Center.

Merck KGaA (Germany)

Merck KGaA is one of the leading players in the single-use bioprocessing market. The company has focused on strengthening its global presence & position by offering high-quality single-use bioprocessing products for end users, increasing investments in R&D, sustainable practices, focus on scalability & flexibility, and brand recognition. With a strong geographic reach, a broad portfolio of single-use bioprocessing products, and continuous expansion in developed and developing regions, the company is expected to grow at a high rate during the forecast period. Between 2022 and 2024, the company made several announcements, including the expansion of its facilities in Germany, China, France, and Ireland, to increase the manufacturing capacity of its biotechnology products. Its expansion activities in Europe and the Asia Pacific in 2024 are further expected to strengthen its position in the single-use bioprocessing market.

Danaher Corporation (US)

Danaher Corporation became one of the most prominent players in the single-use bioprocessing market following its acquisition of Pall Corporation. The company operates as one of the top players in the single-use bioprocessing market through its subsidiary Cytiva (US), with its strong portfolio of single-use bioreactors, filtration systems, and consumables. It focuses on growth strategies, such as agreements, acquisitions, and expansions, to strengthen its global position in the market. For instance, in September 2024, Cytiva, a subsidiary of Danaher Corporation, opened its first Innovation Hub in South Korea, located at the Songdo Global Biotech Cluster in Incheon. This facility is designed to support local biopharmaceutical companies by providing advanced bioprocessing training, technical support, and early access to new technologies.

Market Ranking

The single-use bioprocessing market is consolidated, with four leading players collectively holding 50.0–55.0% of the market share. Sartorius ranks among the leaders in the single-use processing market, offering Biostat STR single-use bioreactors and Ambr development systems that share vessel geometry and control concepts, enabling predictable scale-up from process development to commercial volumes. The single-use processing portfolio is supported by matched bags/flow-paths and integrated single-use sensor options. Danaher Corporation (Cytiva, Pall Biotech) remains one of the major suppliers, with a product portfolio spanning single-use bioreactors, mixing, filtration, pre-packed columns, and control software, enabling participation across upstream and downstream unit operations. Merck KGaA (MilliporeSigma) maintains a significant position through films and bags, TFF and sterile/virus filtration, chromatography hardware and columns, assemblies, and sensor offerings, supported by extensive GMP documentation. Thermo Fisher Scientific holds a meaningful share via HyPerforma/DynaDrive bioreactors, mixing, flow paths, and purification systems, with broad geographic supply capability. Other market players contribute to the remaining 45.0–50.0% of the total market share, which is distributed across component and subsystem providers and niche players, competing on cost, customization, and innovation. Market dynamics in 2024 reflect continued adoption at clinical and selected commercial scales, growth in cell and gene therapy programs, and demand for flexible capacity, alongside supply continuity, change-control, and waste management constraints.

Related Reports:

Single-use Bioprocessing Market by Product (Equipment [Bioreactors, Filtration, Chromatography], Consumables [Filters, Bags, Assemblies, Sensors]), Application (Storage, Mixing), Workflow (Upstream), Molecule Type (mAbs, Vaccines) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com